<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800524</url>
  </required_header>
  <id_info>
    <org_study_id>H2020/755094/2017/IT-01</org_study_id>
    <secondary_id>2018-002722-22</secondary_id>
    <secondary_id>755094</secondary_id>
    <nct_id>NCT03800524</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS</brief_title>
  <acronym>TUDCA-ALS</acronym>
  <official_title>Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanitas Mirasole SpA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dublin, Trinity College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bruschettini S.r.l.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Superiore di Sanità</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Motor Neurone Disease Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanitas Mirasole SpA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled,
      parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as
      add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients will be randomized to one of two treatment arms: TUDCA or identical placebo
      by oral route. The randomization will be performed in a ratio one to one for the two arms.

      TUDCA will be administered orally at the dose of 1 g twice daily (2 g daily) for 18 months.
      Patients will be taking also riluzole at the dose of 50 mg twice daily (100 mg daily).

      Patient randomization will take place after a screening (lead-in) period of 12 weeks (3
      months) with 3 assessments at 6-week intervals. Clinical assessments during the trial phase
      will be performed every three months. This will allow measuring the progression rate before
      and after starting treatment (either active or placebo).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of responder patients</measure>
    <time_frame>18 months</time_frame>
    <description>Identification of the responder patients defined as those showing an improvement of at least 20% in the ALSFRS-R slope</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>18 months</time_frame>
    <description>Survival time measured by death or respiratory insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALS disease functional rating scale - revised version (ALSFRS-R)</measure>
    <time_frame>18 months</time_frame>
    <description>Difference in change from baseline in ALSFRS-R. Each task of the scale is rated on a five-point scale from 0 = can't do, to 4 = normal ability. Individual item scores are summed to produce a reported score ranging from 0 = worst to 48 = best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALS Assessment Questionnaire‐40 (ALSAQ-40)</measure>
    <time_frame>18 months</time_frame>
    <description>Difference in change from baseline in ALSAQ-40. The instrument contains 40 statements that measure five dimensions of health state: Physical Mobility (10 statements), Activities of Daily Living and Independence (10 statements), Eating and Drinking (5 statements), Communication (5 statements), Emotional Functioning (10 statements). The patient must indicate how often (Never, Rarely, Sometimes, Often, or Always) the statement have been true. Dimension scores are coded on a likert scale, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity</measure>
    <time_frame>18 months</time_frame>
    <description>Difference in change from baseline in Forced Vital Capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5‐Dimension-5 Levels (EQ-5D-5L) scale</measure>
    <time_frame>18 months</time_frame>
    <description>Difference in change from baseline in EQ-5D-5L scale. The EQ-5D-5L descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels: 1.no problems, 2.slight problems, 3.moderate problems, 4.severe problems, 5.extreme problems. The patient is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the patient health state. Numbers 1-5 have no arithmetic properties and should not be used as a cardinal score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council (MRC) scale</measure>
    <time_frame>18 months</time_frame>
    <description>Difference in change from baseline in muscle force assessed by the MRC scale. The scale rates muscle strength of 6 muscles (3 at the upper and 3 at the lower limbs), bilaterally. Each muscle is graded from 0 = no movement, to 5 = normal strength, giving a total sum-score that ranges from 0 (total paralysis) to 60 (normal strength).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilaments levels</measure>
    <time_frame>18 months</time_frame>
    <description>Effect of TUDCA on Neurofilament levels in comparison to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMP-9 levels</measure>
    <time_frame>18 months</time_frame>
    <description>Effect of TUDCA on MMP-9 expression in comparison to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Tauroursodeoxycholic acid (TUDCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tauroursodeoxycholic acid (TUDCA) 250 mg capsules
Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
Mode of administration: orally
Duration: 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules identical to active compound
Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
Mode of administration: orally
Duration: 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tauroursodeoxycholic Acid</intervention_name>
    <description>Tauroursodeoxycholic acid (TUDCA) 250 mg capsules
Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
Mode of administration: orally
Duration: 18 months</description>
    <arm_group_label>Tauroursodeoxycholic acid (TUDCA)</arm_group_label>
    <other_name>TUDCA</other_name>
    <other_name>Tudcabil</other_name>
    <other_name>Taurolite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 250 mg capsules
Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
Mode of administration: orally
Duration: 18 months</description>
    <arm_group_label>Reference therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable laboratory-supported, probable, or definite ALS, as defined by El Escorial
             Revised ALS diagnostic criteria 34

          -  Disease duration ≤ 18 months

          -  No swallowing difficulty (4 at ALSFRS-R swallowing subscore)

          -  Able to perform reproducible pulmonary function tests

          -  Forced vital capacity ≥70% of normal

          -  Stable on riluzole treatment for 3 months in the lead-in period

          -  Able to perform reproducible pulmonary function tests

          -  Signed informed consent

        Exclusion Criteria:

          -  Treatment with edaravone

          -  Other causes of neuromuscular weakness

          -  Presence of other neurodegenerative diseases

          -  Significant cognitive impairment, clinical dementia or psychiatric illness

          -  Severe cardiac or pulmonary disease

          -  Other diseases precluding functional assessments

          -  Other life-threatening diseases

          -  At the time of screening, any use of non-invasive ventilation (e.g. continuous
             positive airway pressure, non-invasive bi-level positive airway pressure or
             non-invasive volume ventilation) for any portion of the day, or mechanical ventilation
             via tracheostomy, or on any form of oxygen supplementation

          -  Gastrointestinal disorder that is likely to impair absorption of study drug from the
             gastrointestinal tract

          -  Has taken any investigational study drug within 30 days or five half-lives of the
             prior agent, whichever is longer, prior to dosing

          -  Any clinically significant laboratory abnormality

          -  Other concurrent investigational medications

          -  Active peptic ulcer

          -  Previous surgery or infections of small intestine

          -  Patients unable to easily swallow the treatment pills at time of enrolment

          -  Occurrence of frequent biliary colic, biliary infections, severe pancreatic
             abnormalities

          -  Subjects who weigh 88 lbs (40 kg) or less at screening

          -  Aspartate aminotransferase or alanine aminotransferase concentrations more than 3
             times the upper limit of normal

          -  Creatinine clearance 50 ml/min or less

          -  Previous exposure to bile acids

          -  Any clinically significant neurological, haematological, autoimmune, endocrine,
             cardiovascular, neoplastic, renal, gastrointestinal, or other disorder that, in the
             Investigator's opinion, could interfere with the subject's participation in the study,
             place the subject at increased risk, or confound interpretation of study results

          -  Consideration by the investigator, for any reason, that the subject is an unsuitable
             candidate to receive TUDCA or that the subject is unable or unlikely to comply with
             the dosing schedule or study evaluations

          -  The patient is sexually active and is not willing to use highly effective
             contraception during the study and up to 90 days after the day of last dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Albanese, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Humanitas Mirasole SpA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Albanese, MD</last_name>
    <phone>+39-0282246418</phone>
    <email>alberto.albanese@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Tornese, PhD</last_name>
    <phone>+39-0282246422</phone>
    <email>paolo.tornese@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Van Damme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gwendal Lemasson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Couratier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Camu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Corcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Untucht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus Rüttenscheid</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Torsten Grehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susanne Petri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julian Grosskreutz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Albert C Ludolph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trinity College Dublin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Orla Hardiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Auxologico Italiano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincenzo Silani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEuroMuscular Omnicentre. Fondazione Serena Onlus</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Lunetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Università degli Studi della Campania &quot;Luigi Vanvitelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gioacchino Tedeschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Albanese, MD</last_name>
      <phone>+39-0282246418</phone>
      <email>alberto.albanese@humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Paolo Tornese, PhD</last_name>
      <phone>+39-0282246418</phone>
      <email>paolo.tornese@humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alberto Albanese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlo Colosimo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adriano Chiò, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonard H van den Berg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carolyn Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oliver Hanemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancashire Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suresh Chhetri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amina Chaouch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Sheffield</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher J McDermott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Lambert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.tudca.eu/</url>
    <description>TUDCA-ALS Consortium website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tauroursodeoxycholic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Once the dataset has been analysed, a complete, cleaned, anonymized copy of the final data used in conducting the final analyses will be made available to be used in further studies by the research partners or by other research groups and clinicians.
To prevent misuse and misinterpretation, relevant study metadata (such as the study protocol, case report forms, documentation providing information about the methodology and procedures used to collect the data, definition of variables and statistical code) will be shared in a data repository with a stable URL. Patient anonymity and legal compliance will be assured throughout all the steps of data transfer.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Three months after the data-entry process and final data curation</ipd_time_frame>
    <ipd_access_criteria>Data will be made available only to qualified designated persons (methodologists, biostatisticians) from other academic institutions, on request. User registration will be required in order to access files.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

